Vanda Pharmaceuticals: Buy Rating Reiterated Amidst Strategic Initiatives and Growth Potential
FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate
Vanda Pharmaceuticals Highlights Issues in Gastroparesis Treatment Application Review in Letter to FDA Commissioner
Vanda Asserts FDA Review of Tradipitant Was Flawed
Express News | Vanda Pharmaceuticals: Issued Letter to FDA Regarding Sept. 18, 2024 Crl in Reference to Co's Nda for Tradipitant for Treatment of Gastroparesis
Express News | Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis Nda Review
